Splice it up: Atypical transcripts to boost leukemia immunotherapy

Nicoletta Cieri; Catherine J Wu

doi:10.1016/j.immuni.2021.03.016

Splice it up: Atypical transcripts to boost leukemia immunotherapy

Immunity. 2021 Apr 13;54(4):608-610. doi: 10.1016/j.immuni.2021.03.016.

Authors

Nicoletta Cieri¹, Catherine J Wu²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: cwu@partners.org.

PMID: 33852826
DOI: 10.1016/j.immuni.2021.03.016

Abstract

Neoantigens are prime targets for cancer immunotherapy, but their identification in low mutational burden malignancies remains challenging. In this issue of Immunity, Ehx et al. show that atypical transcripts, and particularly retained introns, expand the spectrum of leukemia immunotherapy targets.

Publication types

Comment

MeSH terms

Antigens, Neoplasm / genetics
Humans
Immunotherapy
Leukemia* / genetics
Leukemia* / therapy
Mutation
Neoplasms*

Substances

Antigens, Neoplasm